Enhancing quality of life


Efficient elimination of tumor cells


Easy intravenous delivery

Our mission is to deliver breakthrough cancer immunotherapies. Our passionate team is working towards improving and prolonging the lives of cancer patients. With a focus on research, translation, clinical development, manufacturing, and commercialization, we are committed to provide safe and effective tumor therapy.

About Us

We are an interdisciplinary team focused on providing breakthrough immunotherapies for cancer patients

Read More

FUSIX Technology

We are working on an immunotherapeutic approach based on a fusogenic oncolytic virus

Read More


We are looking for investors following our pre-seed funding for a planned university spin-out in 2022

Read More


What are we working on?


FUSIX platform

We are finalizing the preclinical data package and pharm/tox studies according to regulatory standards with a focus on liver and pancreatic cancer as first clinical indications.

Combination Therapies

We are developing the FUSIX technology as a platform for immunotherapeutic combination approaches. Immunotherapies have shown their most efficient treatment effects in combination.


We are continuously working on the development of next generation viruses containing therapeutic transgenes that are optimized for immunotherapeutic efficiency and combination therapy.

Let's Chat!

Contact us with any questions or comments.